Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A 25-year cancer study spanning 215,000+ participants is adding whole exome sequencing to sharpen cancer risk predictions across diverse populations. Funded by Regeneron Genetics Center, the project will sequence nearly 75,000 samples by 2027. The goal: catch rare genetic variants that standard genome scans miss — and build risk models that actually work for everyone, not just one group.
The Multiethnic Cohort (MEC) Study — one of the most diverse long-term cancer studies in the U.S. — is leveling up. The 25-year-old study, a collaboration between USC's Keck School of Medicine and the University of Hawaiʻi, will now add whole exome sequencing (WES) to its toolkit, funded and conducted by Regeneron Genetics Center. Nearly 75,000 de-identified participant samples will be sequenced, with results expected by 2027.
So what's the big deal? Traditional genome-wide association studies (GWAS) are great at spotting common genetic variants, but they can miss rare ones. WES zooms in on the protein-coding regions of DNA, uncovering rare or previously unknown variants that could be key to understanding cancer risk — especially in populations that have historically been underrepresented in genetic research.
By the Numbers:
Why it matters: Cancer risk models have long been built on data skewed toward white populations. By integrating WES into one of the nation's most ethnically diverse cohorts, researchers can develop more accurate, equitable predictions — and ultimately guide more targeted screening and prevention for everyone.